Geriatrics
Conference Coverage
ATS: Metformin failed to improve outcomes after COPD exacerbations
Among patients hospitalized for exacerbations from chronic obstructive pulmonary disease, acute administration of metformin had no detectable...
Conference Coverage
Pharmacogenomics for pain meds promising but not ready
Genetic tests for pain treatment efficacy are being marketed in the United States and Australia, but one expert argues that they are not ready for...
Conference Coverage
Cholecystectomy guideline adherence reduces biliary pancreatitis recurrence
Key clinical point: Cholecystectomy within 30 days of acute biliary pancreatitis protects against recurrence. Major finding: Among patients...
Conference Coverage
Ingenol mebutate for AKs gets thumbs-up from patients
Key clinical point: Field therapy for actinic keratoses using topical ingenol mebutate resulted in improved patient-reported outcomes. Major...
Conference Coverage
Reperfusion best predicts post-stroke outcomes
Key clinical point: Early reperfusion may be a better marker of poststroke outcomes than recanalization. Major finding: Reperfusion was associated...
Conference Coverage
ATS: COPD patients on arformoterol tartrate reported better quality of life
Key clinical point: Assessing health status along with lung function provides additional information about the effectiveness of COPD maintenance...
Conference Coverage
Mepolizumab reduces asthma exacerbations more in the elderly
The rate of asthma exacerbations was reduced more among elderly patients than among younger patients treated with mepolizumab vs. placebo as part...
Conference Coverage
Handheld ECG helps spot atrial fibrillation after stroke
Key clinical point: Handheld ECG monitoring may be a practical way to monitor AF risk following a stroke/TIA.
Conference Coverage
ICOO: Massachusetts governor takes on opioid epidemic
The governor of Massachusetts, Charles D. Baker, promises to create viable strategies aimed at addressing the prescription opioid epidemic.
Conference Coverage
ELIXA trial: No cardiovascular risk with GLP-1 receptor agonist lixisenatide
Key clinical point: The glucagon-like peptide 1 (GLP-1) receptor agonist lixisenatide does not increase the risk for cardiovascular problems in...
Conference Coverage
TECOS finds no CV risks for sitagliptin
Key clinical point: Sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor used to lower blood glucose in patients with type 2 diabetes, was not...